September 30, 2020
September 30, 2020 – Lupin Pharmaceuticals has announced the launch of its generic version of Novartis’s
Tykerb® (lapatinib) 250mg tablets. Lapatinib is indicated for the
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health
September 28, 2020
September 28, 2020 – The U.S. FDA has approved an expanded indication for Kalydeco® (ivacaftor),
manufactured by Vertex Pharmaceuticals. The drug is now indicated to treat
September 28, 2020
September 28, 2020 – The U.S. FDA has approved an expanded indication for Haegarda® [C1 esterase
inhibitor (human)], manufactured by CSL Behring. The drug is now indicated
September 28, 2020
September 28, 2020 – The U.S. FDA has approved a new indication for Xeljanz® (tofacitinib), manufactured by Pfizer, to treat patients who are at least two years old and have active
September 27, 2020
September 27, 2020 – The U.S. FDA has approved a new indication for Fetroja® (cefiderocol),
manufactured by Shionogi. The drug is now indicated to treat patients 18 years
September 25, 2020
September 25, 2020 – The U.S. FDA has approved an expanded indication for Eraxis® (anidulafungin),
manufactured by Pfizer. The drug is now indicated to treat candidemia and
September 25, 2020
September 25, 2020 – The U.S. FDA has approved a new indication for Nucala® (mepolizumab),
manufactured by GlaxoSmithKline. Nucala is now indicated to treat patients who
September 23, 2020
September 23, 2020 –Sun Pharmaceuticals has issued a voluntary recall of one lot of Riomet ERTM
(metformin hydrochloride for extended-release oral suspension), 500mg/5mL